London-based Autolus Therapeutics announced plans to locate the company’s U.S. headquarters in Rockville, Maryland.
Members of the wealthy Sackler family behind Purdue Pharma LP pushed the company to boost sales of OxyContin and other opioids even as questions emerged about the extent the drugmaker’s painkillers were being abused, Massachusetts’ attorney general alleged.
AstraZeneca filed a Worker Readjustment and Retraining Notification Act (WARN) notice with the State of Colorado, indicating plans to lay off 210 people in Boulder and Longmont.
A judge dismissed lawsuits filed by 37 different municipal governments pertaining to opioid drugmakers being sued in the state of Connecticut.
U.S. Senator Bernie Sanders and Representative Elijah Cummings plan to introduce legislation aimed at lowering the cost of prescription drugs for U.S. consumers.
U.S. drugmaker Pfizer Inc. said the company was shutting down two manufacturing plants in India that make generic injectables such as penicillin in response to falling demand.
Akorn Inc. received a warning letter from the U.S. Food and Drug Administration following an inspection of the generic drugmaker’s Decatur, Illinois manufacturing plant during 2018.
New York City launched a $100 million health insurance program to cover 600,000 uninsured residents, including those unable to afford coverage and those living in the United States illegally.
Gilead Sciences Inc. is acquiring the global rights to develop and commercialize novel small molecules against two targets from South Korea-based Yuhan Corporation.
A federal judge in Maryland said The Johns Hopkins University, Bristol-Myers Squibb Co. and the Rockefeller Foundation must face a $1 billion lawsuit over their roles in a 1940s U.S. government experiment that infected hundreds of Guatemalans with syphilis.